BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Case

Class period: February 3, 2022 – February 13, 2024
Deadline for lead plaintiff: July 22, 2024

If you would like to serve as lead plaintiff in the Biogen lawsuit, you may submit your contact information at www.glancylaw.com/cases/Biogen-Inc-1/. You may also contact Charles H. LinehanGPM at 310-201-9150, toll free at 888-773-9224, or via email at (email protected) to learn more about your rights.

Complaint filed claims that throughout the Class Period, Defendants failed to disclose to investors that: (1) Biogen exaggerated its efforts to enhance transparency, corporate governance, and compliance controls and procedures, and the effectiveness of such controls and procedures; (2) as a result, Biogen maintained inadequate compliance controls and procedures in connection with its business activities in foreign countries; (3) Biogen and/or its employees engaged in unlawful or otherwise improper conduct in several foreign countries; (4) the foregoing exposed the Company to increased risk of governmental and/or regulatory scrutiny and enforcement, as well as significant legal, financial, and reputational harm; (5) Biogen exaggerated the strength of its AD-related product portfolio, including the Company’s and Eisai’s efforts and the success in launching and providing access to Leqembi; (6) Biogen also downplayed the negative impact that the Reata acquisition would have on its non-GAAP diluted earnings per share in fiscal 2023; (7) all of the foregoing would be likely to have a material adverse effect on Biogen’s 2023 results; and (8) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.